Figure 2.
Exon skipping and pharmacokinetic analysis of 23F- and 23M-treated mdx mice. (a) RT-PCR analysis of muscles from two mdx mice, intramuscularly injected with 2.9 nmol of 23M or 23F contralaterally for 2 consecutive days. (b) RT-PCR analysis of skeletal and heart muscles isolated from mdx mice (four to five mice/group) subcutaneously treated four times per week with 50 mg/kg of 23M, an equimolar amount of 23F or saline for 8 weeks. (c) Antisense oligonucleotide (AON) concentrations in skeletal muscles and heart assessed with a hybridization ligation assay. (d) AON concentrations in liver and kidney as assessed with a hybridization ligation assay. (e) Ratios of AON levels in muscle compared to kidney. (f) Ratios of AON levels in muscle compared to liver. C, untreated control; Dia, diaphragm; F, 23F; Gastr, gastrocnemius; M, 23M; S, saline; Qua, quadriceps; Tib.A, tibialis anterior; Tric, triceps (*T-test for significant P < 0.05). Bars represent means ± SD.